VIRAL CARCINOGENESIS

$0P30FY2000CANIH

University Of California San Diego, La Jolla CA

Investigators

Linked publications & trials

Paper 39640945 Paper 39634576 Paper 39574586 Paper 39512153 Paper 39440943 Paper 39388266 Paper 39317186 Paper 39259813 Paper 39252150 Paper 39158961 Paper 39148716 Paper 39108239 Paper 39108235 Paper 39099090 Paper 39083703 Paper 39083508 Paper 39040198 Paper 38986609 Paper 38959328 Paper 38888861 Paper 38811525 Paper 38795024 Paper 38712081 Paper 38702144 Paper 38672595 Paper 38645172 Paper 38632994 Paper 38588407 Paper 38530242 Paper 38522181 Paper 38513139 Paper 38450560 Paper 38448681 Paper 38393304 Paper 38357279 Paper 38323282 Paper 38316518 Paper 38291075 Paper 38286821 Paper 38233525 Paper 38186234 Paper 38175599 Paper 38164599 Paper 38132831 Paper 38110618 Paper 38102355 Paper 38051586 Paper 38049406 Paper 37961717 Paper 37955563 Paper 37945900 Paper 37862167 Paper 37858759 Paper 37846664 Paper 37839102 Paper 37838757 Paper 37716022 Paper 37699006 Paper 37682073 Paper 37668315 Paper 37662262 Paper 37662229 Paper 37656252 Paper 37655661 Paper 37619986 Paper 37559094 Paper 37553332 Paper 37451831 Paper 37439436 Paper 37433986 Paper 37401034 Paper 37398165 Paper 37378556 Paper 37306759 Paper 37265401 Paper 37241027 Paper 37235748 Paper 37205429 Paper 37195591 Paper 37185743 Paper 37184401 Paper 37160118 Paper 37132280 Paper 37075754 Paper 37034696 Paper 37029916 Paper 36998525 Paper 36948186 Paper 36931394 Paper 36890657 Paper 36889320 Paper 36863895 Paper 36857436 Paper 36854061 Paper 36824750 Paper 36824739 Paper 36807005 Paper 36803553 Paper 36792000 Paper 36724232

Abstract

Description: (Applicant's Description) UCSD Cancer Center's Viral Malignancy Program consists of 12 Members, representing total peer-reviewed funding of $5,511,293 in annual direct costs. During the last year, its Members produced a total of 42 cancer-relevant, peer-reviewed publications, 31% of which were intra- and inter-programmatic collaborations. Research on viral malignancies presents a unique opportunity for our understanding of oncogenesis and a means for targeted intervention. Viruses now etiologically associated with human malignancy include: Epstein-Barr virus (EBV) [non-Hodgkin's lymphoma (NHL) and nasopharyngeal carcinoma]; Hepatitis B and C viruses (HBV and HCV) [hepatocellular carcinoma (HCC)]; Human Immunodeficiency Virus, type 1 (HIV-1) [Kaposi's sarcoma (KS), NHL, and cervical carcinoma in situ]; Human Papilloma Virus (HPV) [skin, genital, and esophageal cancers); Human T-lymphotropic Virus, Type I [adult T-cell leukemia/lymphoma (ATLL)]; and the recently disco vered Human Herpesvirus, Type 8 (HHV-8) [Kaposi's sarcoma, body cavity lymphoma, and possibly multiple myeloma]. The Viral Malignancy Program at the UCSD Cancer Center consists of a longstanding cohesive group of researchers, with wide-ranging expertise in oncogenic viruses. The current primary interests of the Program Members are focused on human retroviruses (including both HIV and HTLV), EBV, and HHV-8, and Members view their association with the Cancer Center as: Helpful to accelerating the development of research collaborations to investigate the pathogenesis of malignancies induced by these viruses. Providing access to rare and valuable shared resources to drive current investigations, develop inter-programmatic investigations, and foster long-term goals. A venue for testing reagents developed to combat these oncogenic viruses and/or their associated malignancies. A pathway to forging new investigative partnerships with prevention and control scientists to study the best methods for combating the spread of malignancy as an infectious disease.

View original record on NIH RePORTER →